Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.